# Automated editorial proposal

- Proposal ID: proposal:83070c219c6b1752394d4d995f3e6415
- Substance: phosphatidylserine
- Suggestion type: new-effect
- Source: [Heptyl prodigiosin from estuarine Zooshikella sp. RANM57 induces caspase-dependent apoptosis and suppresses clonogenic survival in androgen-independent prostate cancer cells](https://doi.org/10.21203/rs.3.rs-11490262/v1)
- PMID: not indexed
- DOI: 10.21203/rs.3.rs-11490262/v1
- Published: 2026-10-27
- Journal: not stated

This file is a review proposal. It is not a published BHWiki article and must not be treated as medical guidance.

## Embedded source snapshot

This abstract snapshot is included so an offline reviewer can check abstract-level claims. It is not a substitute for full-text, version, retraction or licensing verification.

### Abstract

> <title>Abstract</title> <p> Estuarine microbiomes are rich ecological niches for discovering novel secondary metabolites with therapeutic applications. This study focuses on the isolation, purification, structural elucidation, and antineoplastic evaluation of a red pigment from a marine microbial isolate. The bacterium <italic>Zooshikella</italic> sp. RANM57 was isolated from the Netravathi River estuary. Biomass was recovered using an alum-induced flocculation technique and solvent extraction, after which the primary pigment was purified via flash chromatography and structurally characterized using HRLCMS-QTOF and NMR spectroscopy. Anticancer potential was evaluated against human PC-3 prostate cancer cells using MTT and clonogenic assays. The underlying apoptotic mechanism was delineated using Annexin V/PI staining, Caspase-3 quantification, and TUNEL assays. The purified pigment was identified as the tripyrrole alkaloid heptyl prodigiosin based on HRLCMS-QTOF, UV-Vis/FT-IR profiling, and 1D NMR spectral concordance with reported prodiginine features. <italic>In vitro</italic> evaluations revealed significant dose-dependent cytotoxicity against PC-3 cells (IC <sub>50</sub> = 9.00 µg/mL), demonstrating high anticancer efficacy relative to cisplatin. Mechanistic profiling confirmed that cell death occurred exclusively via an intrinsic apoptotic cascade, as evidenced by significant phosphatidylserine externalization (17.60%), executioner Caspase-3 activation (52.45%), and terminal DNA fragmentation (21.25%), without inducing primary necrosis. Furthermore, treatment also reduced clonogenic survival after 24 h exposure and 8-day outgrowth. The successful isolation and characterization of heptyl prodigiosin from <italic>Zooshikella</italic> sp. RANM57 underscores the value of estuarine bacteria in natural product discovery. Our biological evaluations demonstrate that the compound functions as a precise, potent inducer of caspase-associated apoptosis, positioning this tripyrrole scaffold as a highly promising candidate for further anticancer pharmacological development. </p>

## Proposed structured change

```json
{
  "effect": "externalization",
  "context": "Heptyl prodigiosin treatment of human PC-3 prostate cancer cells",
  "measurement": "17.60%"
}
```

## Model rationale

The abstract reports significant phosphatidylserine externalization during heptyl prodigiosin-induced apoptosis in PC-3 cells, without primary necrosis.

## Verbatim evidence from the abstract

> Mechanistic profiling confirmed that cell death occurred exclusively via an intrinsic apoptotic cascade, as evidenced by significant phosphatidylserine externalization (17.60%), executioner Caspase-3 activation (52.45%), and terminal DNA fragmentation (21.25%), without inducing primary necrosis.

## Human review

- [ ] Open the canonical publication and inspect the strongest permitted full text.
- [ ] Verify article version, retraction/correction state, population, exposure, comparator, outcome and limitations.
- [ ] Verify funding/conflict and reuse rights; remove any unsupported field.
- [ ] Apply changes manually to the appropriate Markdown source; do not edit this proposal into public content.
- [ ] Run `bun run content:validate`, `bun run test`, and the normal publisher before merging.
